On May 20, 2025, HC Wainwright & Co. analyst Patrick Trucchio reiterated his "Buy" rating for ATAI Life Sciences (ATAI, Financial), maintaining the price target at $10.00 USD. This rating and price target reflect a continued confidence in ATAI's market position and future stock performance.
The price target remains unchanged from the previous valuation, indicating that the analyst's outlook for ATAI remains stable. This consistent rating suggests a positive sentiment towards the company's ongoing operations and potential growth in the life sciences sector.
Investors following ATAI Life Sciences (ATAI, Financial) may find this reiteration significant, as it underscores the continued support from HC Wainwright & Co. in driving future market performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for ATAI Life Sciences NV (ATAI, Financial) is $8.00 with a high estimate of $11.00 and a low estimate of $5.00. The average target implies an upside of 334.78% from the current price of $1.84. More detailed estimate data can be found on the ATAI Life Sciences NV (ATAI) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, ATAI Life Sciences NV's (ATAI, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for ATAI Life Sciences NV (ATAI, Financial) in one year is $1.68, suggesting a downside of 8.7% from the current price of $1.84. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the ATAI Life Sciences NV (ATAI) Summary page.
